Figure 3.

IFITM is proposed to repress FFV production by disturbing viral assembly at the intracellular and plasma membranes. (a) At the early step (viral entry), IFITM present on the plasma membrane does not efficiently inhibit viral infection. (b) At the late step (viral assembly and release), IFITM present on the intracellular and plasma membranes efficiently inhibits viral assembly by blocking the interaction between pre-assembled capsid and envelope proteins present on membranes. Data are expressed as the mean ± SEM from the triplicates of the three independent experiments. Statistical significance was analyzed with a two-paired Student's t-test. *p < .05, **p < .01.